TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio
Transcode Therapeutics Inc RNAZ
$1.36
▼ -11.69%
($-0.18)
🧊 52W Low
⬇️ Below Yest. Low
🎈 Low Float
📅 Earnings This Week
Open
$1.52
Prev Close
$1.54
Day Range
$1.33 – $1.55
52W Range
$1.45 – $12.60
Market Cap
$26.07M
Beta
1.27
EPS (TTM)
$-47.00
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-04-28 |
| Shares Out. | 16,930,000 |
| Website | transcodetherapeutics.com/ ↗ |
| Phone | 13026587581 |
| Employees | 12 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$6.8M |
| Free Cash Flow | -$22.6M |
| Total Assets | $151.0M |
| Total Liabilities | $12.7M |
| Equity | -$27.7M |
About Transcode Therapeutics Inc
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
Transcode Therapeutics Inc is a publicly traded company under the ticker symbol RNAZ on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2025-06-01)